HomePTCT • NASDAQ
add
PTC Therapeutics, Inc.
Previous close
$70.66
Day range
$69.03 - $72.54
Year range
$35.95 - $87.50
Market cap
5.84B USD
Avg Volume
1.24M
P/E ratio
9.12
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 164.68M | -22.75% |
Operating expense | 106.22M | 20.72% |
Net income | -134.96M | -104.85% |
Net profit margin | -81.96 | -165.16% |
Earnings per share | -1.80 | -425.82% |
EBITDA | -68.72M | -654.61% |
Effective tax rate | 2.96% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.95B | 68.66% |
Total assets | 2.90B | 70.01% |
Total liabilities | 3.10B | 10.74% |
Total equity | -205.31M | — |
Shares outstanding | 82.77M | — |
Price to book | -28.04 | — |
Return on assets | -7.36% | — |
Return on capital | -8.44% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -134.96M | -104.85% |
Cash from operations | -34.27M | -14.23% |
Cash from investing | 34.01M | -87.30% |
Cash from financing | 302.50M | 1,042.78% |
Net change in cash | 312.03M | 22.11% |
Free cash flow | -42.01M | -11,770.05% |
About
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
Founded
Jan 1, 1998
Headquarters
Website
Employees
991
